Management of Brucella endocarditis: results of the Gulhane study

Basit Öğe Kaydı
dc.contributor.authorKoruk, Suda Tekin
dc.contributor.authorErdem, Hakan
dc.contributor.authorKoruk, Ibrahim
dc.contributor.authorErbay, Ayse
dc.contributor.authorTezer-Tekce, Yasemin
dc.contributor.authorErbay, Ali Riza
dc.contributor.authorDayan, Saim
dc.date.accessioned2024-04-24T16:14:52Z
dc.date.available2024-04-24T16:14:52Z
dc.date.issued2012
dc.departmentDicle Üniversitesien_US
dc.description.abstractBrucella endocarditis (BE) is a rare but life-threatening complication of human brucellosis. The aim of this study was to investigate the course of BE along with the therapeutic interrelations. A total of 53 patients with BE hospitalised in 19 health institutions between 2006 and 2011 were included in the Gulhane study. Diagnosis of brucellosis was established by either isolation of Brucella sp. or the presence of antibodies, and the definition of endocarditis was made according to Duke's criteria. There were four treatment groups: ceftriaxone combined with oral antibiotics (Group 1); aminoglycosides combined with oral antibiotics (Group 2); oral antibiotic combinations (Group 3); and aminoglycoside plus ceftriaxone combined with an oral antibiotic (Group 4). Involvement rates of the aortic, mitral and tricuspid valves were 49.1%, 43.4% and 5.7%, respectively. Thirty-two patients (60.4%) had an underlying cardiac valvular problem, including previous prosthetic valve replacement (n = 18). Medical treatment was provided to 32 patients (60.4%), whilst concordant medical and surgical approaches were provided to 21 patients (39.6%). Mortality in Group 1 was 15% (3/20), whilst in Group 2 it was 5.3% (1/19). In Group 3, 25.0% (3/12) of the cases died, whereas none of the cases in Group 4 died. In conclusion, mortality increased 47-fold with pericardial effusion and 25-fold due to congestive heart failure that developed after BE. Although mortality was lower in the aminoglycoside-containing arm (Groups 2 and 4), statistical analysis could not be performed owing to the small number of patients. (C) 2012 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.en_US
dc.identifier.doi10.1016/j.ijantimicag.2012.04.009
dc.identifier.endpage150en_US
dc.identifier.issn0924-8579
dc.identifier.issn1872-7913
dc.identifier.issue2en_US
dc.identifier.pmid22727531en_US
dc.identifier.scopus2-s2.0-84864285354en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage145en_US
dc.identifier.urihttps://doi.org/10.1016/j.ijantimicag.2012.04.009
dc.identifier.urihttps://hdl.handle.net/11468/15472
dc.identifier.volume40en_US
dc.identifier.wosWOS:000306663800009
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofInternational Journal of Antimicrobial Agentsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBrucellosisen_US
dc.subjectEndocarditisen_US
dc.subjectTherapyen_US
dc.subjectMortalityen_US
dc.titleManagement of Brucella endocarditis: results of the Gulhane studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu